Trials / Conditions / Refractory Primary Central Nervous System Neoplasm

Refractory Primary Central Nervous System Neoplasm

19 registered clinical trials studyying Refractory Primary Central Nervous System Neoplasm — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors NCT05278208	Nationwide Children's Hospital	Phase 1 / Phase 2
Withdrawn	Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and You NCT04500548	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors NCT03598244	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H NCT03210714	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Hi NCT03213652	National Cancer Institute (NCI)	Phase 2
Completed	Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or L NCT03323034	Children's Oncology Group	Phase 1
Completed	Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H NCT03213678	National Cancer Institute (NCI)	Phase 2
Completed	Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H NCT03220035	National Cancer Institute (NCI)	Phase 2
Completed	Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lympho NCT03213691	National Cancer Institute (NCI)	Phase 2
Completed	Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Hist NCT03233204	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or NCT03213704	National Cancer Institute (NCI)	Phase 2
Completed	Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patient NCT02975882	Children's Oncology Group	Phase 1
Active Not Recruiting	Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanc NCT03155620	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wi NCT02867592	National Cancer Institute (NCI)	Phase 2
Completed	Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors NCT02808650	Children's Oncology Group	Phase 1
Completed	Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors NCT02780804	National Cancer Institute (NCI)	Phase 1
Completed	Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas NCT02323880	Children's Oncology Group	Phase 1
Completed	Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tu NCT02415153	National Cancer Institute (NCI)	Phase 1
Completed	Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors NCT01709435	National Cancer Institute (NCI)	Phase 1